Cyclized Thioether Peptide Dimers for Selective α4β7 Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current integrin antagonists lack selectivity for α4β7 integrin while interfering with α4β1 integrin-ligand interactions, leading to harmful side effects in treating gastrointestinal autoimmune diseases.
Innovation Solution
Development of cyclized thioether peptides that act as α4β7 antagonists, forming specific thioether bonds to enhance stability, specificity, and potency, thereby inhibiting the binding of α4β7 to MAdCAM without affecting α4β1 integrin interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current integrin antagonists are used to treat gastrointestinal autoimmune diseases, then α4β7 integrin binding is inhibited, but α4β1 integrin-ligand interactions are also interfered with causing harmful side effects
Solution Approach 1:
The patent applies local quality by designing peptides with specific amino acid sequences and structural features (cyclized structures, disulfide bridges, specific secondary structures) that confer selective binding affinity for α4β7 integrin over α4β1 integrin. This localized structural optimization at specific regions of the peptide enables differential interaction with the two integrin types, achieving high selectivity and avoiding off-target effects on α4β1.
2Reliability
If peptide stability is increased through cyclization and thioether bonds, then specificity and potency are enhanced, but molecular complexity increases
Solution Approach 1:
The patent merges multiple stabilizing features into a unified peptide architecture: cyclization to constrain the backbone, disulfide bridges to lock specific conformations, and thioether bonds to enhance structural rigidity. By combining these elements into an integrated design, the peptide achieves enhanced stability and specificity while the complexity is managed through systematic integration rather than additive accumulation of separate features.
Data Source
AI summary
The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of α4β7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.